Generic Name and Formulations:
Hepatitis A vaccine, inactivated 720 ELISA Units (EL.U.) per 0.5mL (pediatric), or 1440 EL.U. per 1mL (adult); susp for IM inj; aluminum adsorbed; contains neomycin (trace); preservative-free.
Indications for HAVRIX:
Hepatitis A immunization.
Inject into deltoid, preferably at least 2 weeks before expected exposure. >18yrs: 1440 EL.U. once IM; give booster dose 6–12 months after initial course.
Inject IM preferably at least 2 weeks before expected exposure. <12months: not recommended. 12months–18yrs: 720 EL.U. once IM; give booster dose 6–12months after initial course.
Neomycin allergy. Previous hypersensitivity reaction to hepatitis A-containing vaccine.
Have epinephrine (1:1000) inj available. Fever. Bleeding disorders. Immunodeficiency (may have suboptimal response). If given with immune globulin, use separate syringe and different site. Latex allergy. Pregnancy (Cat.C). Nursing mothers.
Immunosuppressives may reduce efficacy. Concomitant vaccines: see literature.
Inj site reactions, headache, fatigue, fever, malaise, anorexia, GI upset.
Single-dose vials—10; Single-dose prefilled Tip-Lok syringes—5 (without needles)
Endocrinology Advisor Articles
- Diet Quality and Glycemic Control in Women With Gestational Diabetes
- Most Foods Containing Fructose Do Not Have Harmful Effect on Glycemic Control
- Effects of a Low-Carbohydrate Diet on Weight Loss Maintenance
- Hypothyroidism Treatment No Longer Available
- Endocrine-Disrupting Chemicals in Personal Care Products Linked to Early Puberty
- Normalized HbA1c Levels Facilitate Improved Neuropathy Outcomes in T2D
- Parental Perception of Child Weight Status Predicted by Child BMI z Scores
- Fear Impacts Quality of Life for Young Adults With Type 1 Diabetes
- Five-Year Efficacy Data Announced for Liletta Intrauterine System
- AMA Code of Medical Ethics Guides Physicians in Fighting Harmful Online Health Information